These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 33313898)

  • 1. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY.
    Strand V; Tundia N; Wells A; Buch MH; Radominski SC; Camp HS; Friedman A; Suboticki JL; Dunlap K; Goldschmidt D; Bergman M
    Rheumatology (Oxford); 2021 Jul; 60(7):3209-3221. PubMed ID: 33313898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT.
    Strand V; Pope J; Tundia N; Friedman A; Camp HS; Pangan A; Ganguli A; Fuldeore M; Goldschmidt D; Schiff M
    Arthritis Res Ther; 2019 Dec; 21(1):272. PubMed ID: 31815649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.
    Bergman M; Tundia N; Martin N; Suboticki JL; Patel J; Goldschmidt D; Song Y; Wright GC
    Arthritis Res Ther; 2022 Jun; 24(1):155. PubMed ID: 35751108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.
    Strand V; Tundia N; Bergman M; Ostor A; Durez P; Song IH; Enejosa J; Schlacher C; Song Y; Fleischmann R
    Rheumatology (Oxford); 2021 Dec; 60(12):5583-5594. PubMed ID: 33590829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs.
    Strand V; Schiff M; Tundia N; Friedman A; Meerwein S; Pangan A; Ganguli A; Fuldeore M; Song Y; Pope J
    Arthritis Res Ther; 2019 Dec; 21(1):263. PubMed ID: 31791386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.
    Bingham CO; Walker D; Nash P; Lee SJ; Ye L; Hu H; Khalid JM; Combe B
    Arthritis Res Ther; 2022 Jan; 24(1):11. PubMed ID: 34980223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment.
    Schiff M; Takeuchi T; Fleischmann R; Gaich CL; DeLozier AM; Schlichting D; Kuo WL; Won JE; Carmack T; Rooney T; Durez P; Shaikh S; Hidalgo RP; van Vollenhoven R; Zerbini CAF
    Arthritis Res Ther; 2017 Sep; 19(1):208. PubMed ID: 28923098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
    Strand V; Kaine J; Alten R; Wallenstein G; Diehl A; Shi H; Germino R; Murray CW
    Arthritis Res Ther; 2020 Oct; 22(1):243. PubMed ID: 33059710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
    Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
    Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
    Tanaka Y; Takeuchi T; Izutsu H; Kaneko Y; Kato D; Fukuda M; Rokuda M; Schultz NM
    Arthritis Res Ther; 2021 Aug; 23(1):221. PubMed ID: 34429152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.
    van Vollenhoven R; Strand V; Takeuchi T; Chávez N; Walter PM; Singhal A; Swierkot J; Khan N; Bu X; Li Y; Penn SK; Camp HS; Aelion J
    Arthritis Res Ther; 2024 Jul; 26(1):143. PubMed ID: 39075620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.
    Genovese MC; Han C; Keystone EC; Hsia EC; Buchanan J; Gathany T; Murphy FT; Wu Z; Parasuraman S; Rahman MU
    J Rheumatol; 2012 Jun; 39(6):1185-91. PubMed ID: 22505702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
    Jansen JP; Buckley F; Dejonckheere F; Ogale S
    Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
    van Vollenhoven R; Takeuchi T; Pangan AL; Friedman A; Mohamed MF; Chen S; Rischmueller M; Blanco R; Xavier RM; Strand V
    Arthritis Rheumatol; 2020 Oct; 72(10):1607-1620. PubMed ID: 32638504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.